The MM120 abnormal liver impairment Study
Understanding the Effects of Liver Function on a Potential Investigational Treatment
The MM120 abnormal liver impairment Study
Understanding the Effects of Liver Function on a Potential Investigational Treatment
The MM120 abnormal liver impairment Study
Understanding the Effects of Liver Function on a Potential Investigational Treatment
About the MM120 Study (MM120-106)
This clinical research study is designed to learn more about how liver function may impact the way a potential investigational treatment called MM120 is processed by the body. Researchers are studying the safety, tolerability, and pharmacokinetics (how the drug is absorbed, distributed, metabolized, and excreted) of MM120 in adults with adults with mild to moderate abnormal liver impairment (due to long-term liver disease).
MM120 is an oral, investigational formulation of LSD D-tartrate, which is being studied for its effects on the body and mind. All participants will receive a single dose of MM120 during their visit and will be closely monitored by trained medical staff throughout the study. The study lasts up to 44 days in total.
The investigational drug will be provided to participants by healthcare professionals, and will be monitored through regular outpatient clinic visits through the entire course of study treatment.
MM120 is an oral, investigational formulation of LSD D-tartrate, which is being studied for the treatment of generalized anxiety disorder (GAD) and other psychiatric conditions. This specifc study is to learn how the drug is abosrbed, distributed, metabolized, and excreted in adults with hepatic impairment. All participants will receive a single dose of MM120 during their visit and will be closely monitored by trained medical staff throughout the study. The study lasts up to 44 days in total.
The investigational drug will be provided to participants by healthcare professionals, and will be monitored through inpatient and outpatient clinic visits through the entire course of study treatment.
Study Criteria
If you, or someone you know, is interested in enrolling in this study for abnormal liver impairment, you or they may be eligible to participate if you:
- Between 18 and 65 years old.
- Able to stay at a research clinic for 4 days.
- Comfortable with taking part in a psychedelic medicine study (involving LSD in a controlled setting).
- Willing to follow study procedures and attend follow-up visits.
*Other eligibility criteria apply.
All participants will receive study-related care, evaluations, and study medication at no cost. Compensation for time and travel may be provided. No insurance is required to participate.
Participation Overview
All participants who are eligible and successfully enroll in this study will participate for up to approximately 44 days, including screening, inpatient monitoring, and follow-up.
- Screening Period: Up to 35 days to confirm eligibility
- Inpatient Stay: 4 days at the research site, including MM120 dosing and close medical monitoring
- Follow-Up: One phone check-in around Day 6 and a final in-person visit on Day 9
Qualified participants will receive all study-related care and study medication at no cost, and compensation for time and travel may be available.
Do you know someone age 18 to 65 who has Abnormal Liver Impairment?
They may be eligible to participate in this clinical study. Consider sharing information with them about how they can learn more.